Epoxyeicosatrienoic acid pathway in human health and diseases
- PMID:23011468
- DOI: 10.1097/FJC.0b013e318273b007
Epoxyeicosatrienoic acid pathway in human health and diseases
Abstract
In response to endothelial cell activation, arachidonic acid can be converted by cytochrome P450 (CYP) epoxygenases to epoxyeicosatrienoic acids (EETs), which have potent vasodilator and anti-inflammatory properties. EETs are rapidly degraded in vivo to the less active dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH). Since the beginning of the 2000s, the role of EET pathway in human health and its alteration in diseases has been shown by measuring EETs/DHET levels in blood, by evaluating the relationship between CYP/sEH gene polymorphisms, which modify enzyme activity and thus EETs/DHET level, and by assessing the inhibitory effect of the local administration of CYP epoxygenase inhibitor on endothelium-dependent dilatation. By combining these functional and biological approaches, we demonstrated that EETs are the endothelial factors released by CYP epoxygenases involved in the flow-mediated dilatation of conduit arteries in healthy subjects, together with the impairment of EET availability in essential hypertensive patients at this level. The modulation of EET pathway now emerges as a new promising pharmacological target that may improve the clinical management of patients at high cardiovascular risk. In this respect, the restoration of EET availability using a new class of agents, the inhibitors of sEH, gave promising results in various animal models of cardiovascular diseases, reducing blood pressure and target organ damage, and a first product has entered clinical evaluation.
Similar articles
- DiscrEET regulators of homeostasis: epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation.Fleming I.Fleming I.Trends Pharmacol Sci. 2007 Sep;28(9):448-52. doi: 10.1016/j.tips.2007.08.002. Epub 2007 Aug 30.Trends Pharmacol Sci. 2007.PMID:17764757
- The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.Xu X, Zhang XA, Wang DW.Xu X, et al.Adv Drug Deliv Rev. 2011 Jul 18;63(8):597-609. doi: 10.1016/j.addr.2011.03.006. Epub 2011 Apr 6.Adv Drug Deliv Rev. 2011.PMID:21477627Review.
- Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?Bellien J, Joannides R, Richard V, Thuillez C.Bellien J, et al.Pharmacol Ther. 2011 Jul;131(1):1-17. doi: 10.1016/j.pharmthera.2011.03.015. Epub 2011 Apr 14.Pharmacol Ther. 2011.PMID:21514320Review.
- Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids.Shahabi P, Siest G, Visvikis-siest S.Shahabi P, et al.Drug Metab Rev. 2014 Feb;46(1):33-56. doi: 10.3109/03602532.2013.837916. Epub 2013 Sep 16.Drug Metab Rev. 2014.PMID:24040964Review.
- Arachidonic acid cytochrome P450 epoxygenase pathway.Spector AA.Spector AA.J Lipid Res. 2009 Apr;50 Suppl(Suppl):S52-6. doi: 10.1194/jlr.R800038-JLR200. Epub 2008 Oct 23.J Lipid Res. 2009.PMID:18952572Free PMC article.Review.
Cited by
- Epoxyeicosatrienoic acids, hypertension, and kidney injury.Imig JD.Imig JD.Hypertension. 2015 Mar;65(3):476-82. doi: 10.1161/HYPERTENSIONAHA.114.03585. Epub 2015 Jan 12.Hypertension. 2015.PMID:25583156Free PMC article.Review.No abstract available.
- Inducible endothelium-derived hyperpolarizing factor: role of the 15-lipoxygenase-EDHF pathway.Campbell WB, Gauthier KM.Campbell WB, et al.J Cardiovasc Pharmacol. 2013 Mar;61(3):176-87. doi: 10.1097/FJC.0b013e31828165db.J Cardiovasc Pharmacol. 2013.PMID:23249676Free PMC article.Review.
- Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics.Imig JD.Imig JD.Pharmacol Ther. 2018 Dec;192:1-19. doi: 10.1016/j.pharmthera.2018.06.015. Epub 2018 Jun 30.Pharmacol Ther. 2018.PMID:29964123Free PMC article.Review.
- Inside epoxyeicosatrienoic acids and cardiovascular disease.Tacconelli S, Patrignani P.Tacconelli S, et al.Front Pharmacol. 2014 Nov 10;5:239. doi: 10.3389/fphar.2014.00239. eCollection 2014.Front Pharmacol. 2014.PMID:25426071Free PMC article.Review.
- The Natural Flavonoid Pinocembrin: Molecular Targets and Potential Therapeutic Applications.Lan X, Wang W, Li Q, Wang J.Lan X, et al.Mol Neurobiol. 2016 Apr;53(3):1794-1801. doi: 10.1007/s12035-015-9125-2. Epub 2015 Mar 7.Mol Neurobiol. 2016.PMID:25744566Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources